NEWS: MAY 2005

-05/31/2005-

La Jolla Pharmaceutical Co.'s finances enough just to keep the company going until Q1/2006. To read article click here.

Qiagen NV acquires artus GmbH. To read article click here.

Affymetrix Inc. to acquire ParAllele BioScience Inc. To read article click here.

-05/26/2005-

Press Release: Barnstead Genevac has introduced a new optimised concentrator for safe and productive preparation of DNA samples. The new system is part of the miVac range of affordable centrifugal concentrators for molecular biology applications. To read press release click here.

Neurocrine Biosciences Inc. submits New Drug Application (NDA) to the FDA for indiplon tablets for the treatment of insomnia. To read article click here.

Pharmacopeia Drug Discovery Inc. forms alliance with Columbia University and Cold Spring Harbor Laboratory. To read article click here.

ARIAD Pharmaceuticals Inc. to begin Phase Ib clinical trials of mTOR inhibitor AP23573 for cancer treatment. To read article click here.

-05/25/2005-

Press Release: Radleys Discovery Technologies, market leader in innovative tools for parallel chemistry, have introduced a new range of reduced volume reaction vessels further extending the utility of their popular Carousel 6-Place, Carousel Reaction Station & Metz Syn10 products. To read press release click here.

Pharmacopeia receives milestone payment form Organon International Inc. To read article click here.

-05/24/2005-

Press Release: Available from Moritex is an updated version of their popular 80-page Skin Counselling Advice and Support Handbook. To read press release click here.

Press Release: In a recently published report from the UK Royal Society of Chemistry (MicroAnalytical Group) assessing the current proficiency of microanalysis in end user laboratories - four out of the top five laboratories used the CE440 Elemental Analyser from Exeter Analytical. To read press release click here.

ViroPharma Incorporated to intiate Phase Ib clinical trials of HCV-796 for hepatitis C. To read article click here.

-05/23/2005-

Press Release: Available from Porvair Sciences are a range of disposable Microplate Reservoir Trays designed for laboratories looking to achieve high-throughput and maximise recovery of precious reagents and samples. To read press release click here.

-05/20/2005-

Press Release: GALAPAGOS NV & ASINEX LTD. INITIATE DRUG DISCOVERY COLLABORATION IN BONE AND JOINT DISEASES. To read press release click here.

Press Release: Morphochem provides novel lead compounds for further development from successful collaboration. To read press release click here.

Praecis Pharmaceuticals Inc. to cut 60 percent of its staff. To read article click here.

FDA approves Depomed Inc.'s antibiotic Proquin XR for urinary tract infections. To read article click here.

Roswell Park Cancer Institute acquires SEQUENOM, Inc.'s MassARRAY® system for genetic cancer research. To read article click here.

Actavis Group to acquire Amide Pharmaceutical Inc. To read article click here.

-05/19/2005-

South Korean scientist clone embryos for the treatment of injuries and diseases. To read article click here.

Rincon Pharmaceuticals Inc. and Biogen Idec Inc. form research collaboration. To read article click here.

Solexa Inc. to cut about 17 percent of its work force. To read article click here.

Threshold Pharmaceuticals Inc. posts positive results of Phase II clinical trials of TH-070 (lonidamine) for the treatment of benign prostatic hyperplasia (BPH). To read article click here.

Chiron Corporation and Enanta Pharmaceuticals form alliance to develop and commercialize Chiron's hepatitis C virus (HCV) protease inhibitors. To read article click here.

Sirtris Pharmaceuticals to in-lincense sirtuin compounds from ashington University School of Medicine for their use as class III histone deacetylase inhibitors for neuroprotection. To read article click here.

-05/18/2005-

Guilford Pharmaceuticals Inc. announces new data from its NAALADase inhibitor program at ASCO. To read article click here.

STAT-3 gene required for the generation of B-lymphomas in mice. To read article click here.

deCODE genetics initiates Phase II clinical trials in asthma. To read article click here.

-05/17/2005-

Telik Inc. announces positive results of TELCYTA in combination with Cisplatin in first-line non-small cell lung cancer. To read article click here.

Spectrum Pharmaceuticals acquires worldwide rights for Lucanthone in Phase II clinical trials. To read article click here.

Lexicon Genetics Incorporated and Organon form collaboration on novel biotherapeutics. To read article click here.

Serono and NovImmune form alliance to develop and commercialize NovImmune's NI-0401 and NI-0501 fully human monoclonal antibodies. To read article click here.

InNexus Biotechnology Inc. and Mayo Clinic form monoclonal antibody development collaboration. To read article click here.

ACADIA Pharmaceuticals expands technology platform to target tyrosine kinase linked receptors (RTKs) for CNS and cancer treatments. To read article click here.

Odyssey Thera Inc. and Pfizer Inc. expand compound profiling collaboration. To read article click here.

-05/16/2005-

ImClone Systems Inc. and Bristol-Myers Squibb Co. announce positive data on Erbitux for cancer treatment at the ACSO meeting. To read article click here.

Avanir Pharmaceuticals' CEO Gerald J. Yakatan resigns. To read article click here.

Invitrogen Corp. acquires Caltag Laboratories for $20 million in cash. To read article click here.

Introgen Therapeutics Inc.'s INGN 225, a vaccine targeting p53, sensitizes tumors to platinum and taxane-based chemotherapies. To read article click here.

Revlimid, a thalidomide-like drug, found to be effective against myelodysplastic syndrome (MDS). To read article click here.

GlaxoSmithKline to delay filing of experimental cancer pill Lapatinib until late 2006 or early 2007. To read article click here.

Magellan Biosciences acquires TekCel. To read article click here.